Cancer Cell Patents (Class 424/155.1)
-
Patent number: 10391146Abstract: Compositions and methods for inhibiting metastatic cancer cells. The compositions comprise nanoparticles which have incorporated therein leukocyte adhesion molecules and therapeutic molecules exposed on their surface. The nanoparticles may be provided attached to leukocytes. Introduction of these compositions in to the circulation of individuals results in inhibition and reduction of metastatic cancer cells.Type: GrantFiled: August 4, 2014Date of Patent: August 27, 2019Assignee: Cornell UniversityInventors: Michael R. King, Michael J. Mitchell, Kuldeepsinh Rana, Elizabeth C. Wayne, Chris B. Schaffer, Siddarth Chandrasekaran
-
Patent number: 10350266Abstract: The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein alone or in combination with IL-2 and/or an immune checkpoint inhibitor. The invention also provides composition for use in such methods.Type: GrantFiled: May 30, 2017Date of Patent: July 16, 2019Assignee: NODUS THERAPEUTICS, INC.Inventors: Jennifer R. Cochran, Karl Dane Wittrup
-
Patent number: 10338071Abstract: A repeatable method for detecting circulating tumor cells in vitro is provided. The method involves combining a test sample from a patient suspected of having circulating tumor cells, and a non-lytic adenoviral system, and culture media for the cells. The adenoviral system utilizes (i) a first replication-defective adenoviral particle in which an expression cassette is packaged, said expression cassette comprising an adenoviral 5? and 3? ITRs and a tumor-specific promoter; and (ii) a coding sequence for a reporter protein which is expressed in the presence of circulating tumor cells, and an adenoviral 3? ITR. The test sample and the non-lytic adenoviral system are incubated for a sufficient time to permit expression of the reporter protein, and measuring reporter protein expression in the test samples, whereby presence of reporter expression indicates the presence of circulating tumor cells in the sample. Because the system is non-lytic, the testing can be repeated on the cells which remain viable in culture.Type: GrantFiled: November 14, 2017Date of Patent: July 2, 2019Assignee: The Trustees of the University of PennsylvaniaInventors: Stephen M. Hahn, Jay F. Dorsey, Gary D. Kao, Emigdio Reyes
-
Patent number: 10328149Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)n—S—B12H112? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: GrantFiled: June 12, 2015Date of Patent: June 25, 2019Assignee: TENBORON OYInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Patent number: 10307479Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.Type: GrantFiled: October 31, 2016Date of Patent: June 4, 2019Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Nai-Kong V. Cheung
-
Patent number: 10304219Abstract: A set of first modality data is provided to an intra-reconstruction motion correction method. The set of first modality data includes a plurality of views. A set of second modality data is provided to the method. A motion estimate is generated for each of the plurality of views in the set of first modality data by registering the set of first modality data with the set of second modality data. A motion corrected model of the set of first modality data is generated by a forward projection including the motion estimate.Type: GrantFiled: June 12, 2015Date of Patent: May 28, 2019Assignee: Siemens Medical Solutions USA, Inc.Inventors: Michal Cachovan, Alexander Hans Vija
-
Patent number: 10251906Abstract: In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 11, 2014Date of Patent: April 9, 2019Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Jindrich Henry Kopecek, Jiyuan Yang, Te-Wei Chu
-
Patent number: 10245279Abstract: Method for immobilizing a target microorganism or target chemical found in a mammal includes introducing into a gastrointestinal tract of the mammal immobilization particles including immobilization molecules capable of attaching to the target microorganism or the target chemical, which immobilization molecules are attached to one or more portions of a structure that is capable of inhibiting contact between tissues of the gastrointestinal tract and the target microorganisms or target chemicals attached to the immobilization molecules.Type: GrantFiled: January 20, 2016Date of Patent: April 2, 2019Assignee: NuBiome, Inc.Inventor: Brian C. Lue
-
Patent number: 10179810Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: GrantFiled: June 13, 2014Date of Patent: January 15, 2019Assignee: Boehringer Ingelheim International GmbHInventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
-
Patent number: 10118970Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies. In general, the multispecific antibodies are made by methods involving the steps of altering the nucleic acid sequence encoding the light chain variable domain (VL) of an antibody that binds a first epitope, and selecting a multispecific antibody capable of binding the first and a second epitope.Type: GrantFiled: August 17, 2007Date of Patent: November 6, 2018Assignee: Genentech, Inc.Inventors: Germaine Fuh, Jenny M. Bostrom
-
Patent number: 10077316Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: GrantFiled: December 25, 2014Date of Patent: September 18, 2018Assignee: National University Corporation, Kochi UniversityInventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Patent number: 10072082Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.Type: GrantFiled: November 24, 2015Date of Patent: September 11, 2018Assignee: Bristol-Myers Squibb CompanyInventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
-
Patent number: 10017767Abstract: An agent that increases YAP1 levels for use in the treatment of hematopoietic disorders.Type: GrantFiled: November 5, 2013Date of Patent: July 10, 2018Assignees: FONDAZIONE CENTRO SAN RAFFAELE, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Giovanni Tonon, Francesca Cottini, Kenneth Carl Anderson
-
Patent number: 10000575Abstract: An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.Type: GrantFiled: April 29, 2014Date of Patent: June 19, 2018Assignees: OGD2 PHARMA, UNIVERSITE DE NANTESInventors: Stephane Birkle, Denis Cochonneau, Mylene Dorvillius, Jean-Marc Le Doussal, Mickael Terme
-
Patent number: 9926377Abstract: The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: May 21, 2015Date of Patent: March 27, 2018Assignee: Genentech, Inc.Inventors: Paul Polakis, Youjun Chen
-
Patent number: 9890208Abstract: The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.Type: GrantFiled: September 17, 2014Date of Patent: February 13, 2018Assignee: Maine Medical CenterInventors: Peter C. Brooks, Leif Oxburgh, Jennifer M. Caron
-
Patent number: 9879267Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.Type: GrantFiled: March 12, 2009Date of Patent: January 30, 2018Assignee: Genentech, Inc.Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
-
Patent number: 9873915Abstract: The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3).Type: GrantFiled: October 16, 2008Date of Patent: January 23, 2018Assignees: Ventana Medical Systems, Inc., University of CincinnatiInventors: Mana Mirza, Elizabeth Shaughnessy, Georg F. Weber, John K. Hurley, Kristie A. Vanpatten, Gary Pestano
-
Patent number: 9855291Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: November 3, 2009Date of Patent: January 2, 2018Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 9844607Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.Type: GrantFiled: February 5, 2014Date of Patent: December 19, 2017Assignees: SANOFI, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Jochen Kruip, Sanjiv S. Gambhir, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken, Richard Kimura, Arutselvan Natarajan, Ohad Ilovich
-
Patent number: 9815897Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.Type: GrantFiled: May 2, 2014Date of Patent: November 14, 2017Assignee: AnaptysBio, Inc.Inventors: David J. King, Marilyn Kehry
-
Patent number: 9803015Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.Type: GrantFiled: February 18, 2016Date of Patent: October 31, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon
-
Patent number: 9797904Abstract: The present invention relates to a method for diagnosing the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a diagnostic biomarker. The present invention also relates to a method for predicting the prognosis of the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a prognostic biomarker. The present invention further relates to a method to suppress proliferation of lung tumor cells in a subject, decrease growth of lung tumor cells in a subject, or improve survival of a subject with lung cancer by using isocitrate dehydrogenase 1 as a therapeutic target.Type: GrantFiled: September 13, 2012Date of Patent: October 24, 2017Assignee: Cancer Hospital, Chinese Academy of Medical SciencesInventors: Jie He, Fengwei Tan, Zhaoli Chen, Nan Sun
-
Patent number: 9797906Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.Type: GrantFiled: May 6, 2013Date of Patent: October 24, 2017Assignee: Wayne State UniversityInventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
-
Patent number: 9789202Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.Type: GrantFiled: September 5, 2012Date of Patent: October 17, 2017Assignees: HANMI SCIENCE CO., LTD., BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu
-
Patent number: 9783599Abstract: The invention provides LM-1 antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. The invention also provides antibodies, functional fragments, modified and variant forms that bind to LM-1 antigen (e.g., NONO/nmt55). Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One method includes treating metastasis of a neoplasia, tumor or cancer in a subject in need of treatment by administering to the subject an amount of a LM-1 antibody, an antibody that binds to LM-1 antigen, or a functional fragment thereof, effective to treat metastasis of the neoplasia, tumor or cancer in the subject.Type: GrantFiled: March 14, 2014Date of Patent: October 10, 2017Assignee: Patrys LimitedInventors: Heinz Peter Vollmers, Stephanie Ute Brandlein, Andreas Thalheimer, Leodevico L. Ilag, Barbara E. Power, Lishanthi Udabage, Frank Hensel, Frank Schoenen, Arndt-Rene Kelter, Christopher Garth Hosking
-
Patent number: 9782481Abstract: A magnetic nanoparticles including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.Type: GrantFiled: April 19, 2016Date of Patent: October 10, 2017Assignee: UNIVERSITY OF WYOMINGInventors: Baskaran Thyagarajan, Padmamalini Baskaran
-
Patent number: 9777261Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.Type: GrantFiled: June 15, 2015Date of Patent: October 3, 2017Assignee: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Ho Min Kim, Jung-Eun Lee, Chan Kim, Gou Young Koh, Gyun Min Lee
-
Patent number: 9777065Abstract: The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.Type: GrantFiled: July 1, 2015Date of Patent: October 3, 2017Assignee: Omeros CorporationInventors: W. Jason Cummings, Munehisa Yabuki, John B. Leppard, Christi L. Wood, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
-
Patent number: 9696312Abstract: The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.Type: GrantFiled: September 4, 2012Date of Patent: July 4, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Nicole Suciu-Foca, George Vlad, Chih-Chao Chang, Zhuoru Liu, Adriana Ioana Colovai
-
Patent number: 9683048Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.Type: GrantFiled: January 23, 2015Date of Patent: June 20, 2017Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 9676839Abstract: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies.Type: GrantFiled: December 2, 2009Date of Patent: June 13, 2017Assignee: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Thierry Wurch
-
Patent number: 9669081Abstract: The present invention relates to prostate cancer markers, compositions comprising such markers, and methods of using such markers to induce or increase an immune response against prostate cancer. An immune response against the markers correlates with an immune response, in particular a humoral immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and/or amelioration of at least one symptom associated with prostate cancer.Type: GrantFiled: September 19, 2014Date of Patent: June 6, 2017Assignee: ADURO GVAX, INC.Inventors: Karin Jooss, Thomas Harding, Minh Nguyen, Kathryn E. Koprivnikar
-
Patent number: 9642921Abstract: This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.Type: GrantFiled: December 20, 2013Date of Patent: May 9, 2017Assignee: Tocagen Inc.Inventors: Joan M. Robbins, Douglas J. Jolly, Derek G. Ostertag, Tiffany Huang, Harry E. Gruber
-
Patent number: 9605050Abstract: A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.Type: GrantFiled: November 26, 2014Date of Patent: March 28, 2017Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventor: Lai-Xi Wang
-
Patent number: 9593314Abstract: The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition.Type: GrantFiled: March 8, 2013Date of Patent: March 14, 2017Assignee: Covagen AGInventors: Simon Brack, Frédéric Mourlane, Isabella Toller, Richard Woods, Julian Bertschinger, Dragan Grabulovski, Babette Schade, Kristina Klupsch, Helen Hachemi
-
Patent number: 9551035Abstract: The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.Type: GrantFiled: February 15, 2011Date of Patent: January 24, 2017Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, QUEEN MARY UNIVERSITY OF LONDONInventors: Christoph Schröder, Jörg Hoheisel, Tatjana Crnogorac-Jurcevic
-
Patent number: 9549981Abstract: The invention provides a blocking ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex, for sequential use in inhibiting the growth of tumor cell.Type: GrantFiled: June 22, 2012Date of Patent: January 24, 2017Assignee: Philogen S.p.A.Inventor: Kathrin Schwager
-
Patent number: 9506925Abstract: Cells within liver tumor mass comprise a unique set of proteins/tumor antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumor. The presence of tumor antigens couples the production of auto-antibodies against these tumor antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumor antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26, to complement the conventional diagnostic methods.Type: GrantFiled: July 2, 2014Date of Patent: November 29, 2016Assignee: DRAGON VICTORY DEVELOPMENT LTD.Inventors: Cornelia Wing Yin Man, Norman Fung Man Wai, Bing Lou Wong, Benjamin Chi Yin Wai
-
Patent number: 9505847Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.Type: GrantFiled: August 22, 2012Date of Patent: November 29, 2016Assignee: CNJ HOLDINGS INCInventors: Robyn Cassan, Jody Berry, Darrell Johnstone, Derek Toth, Joyee Antony George, Bonnie Tighe
-
Patent number: 9493575Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.Type: GrantFiled: July 14, 2015Date of Patent: November 15, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
-
Patent number: 9493740Abstract: The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).Type: GrantFiled: September 8, 2011Date of Patent: November 15, 2016Assignee: Baylor College of MedicineInventors: Malcolm Brenner, Gianpietro Dotti, Nabil Ahmed, Claudia Rossig, Stephen M. G. Gottschalk, Zakaria Grada
-
Patent number: 9476024Abstract: The invention relates to a culture substrate having thermoresponsive microgel particles that have a thermoresponsive polymer and modulator particles fixed to the carrier area of the substrate. The modulator can be a substance that has an adhesion capability with biological cells or a substance that causes cellular reactions that are inducible to binding to surface receptors of biological cells. Methods for preparation and use in culturing cells are given.Type: GrantFiled: March 21, 2011Date of Patent: October 25, 2016Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.Inventors: Claus Duschl, Andreas Lankenau, Stephan Schmidt, Thomas Hellweg, Erik Wischerhoff, Andre Laschewsky, Jean-Francois Lutz
-
Patent number: 9422234Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.Type: GrantFiled: November 26, 2008Date of Patent: August 23, 2016Assignee: The Johns Hopkins UniversityInventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
-
Patent number: 9416176Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.Type: GrantFiled: April 9, 2014Date of Patent: August 16, 2016Assignee: Atlas Antibodies ABInventors: Mathias Uhlen, Fredrik Ponten, Karin Jirstrom
-
Patent number: 9402898Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.Type: GrantFiled: January 22, 2013Date of Patent: August 2, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Scott M. Walsh, Daniel B. Dix
-
Patent number: 9382332Abstract: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation.Type: GrantFiled: May 8, 2013Date of Patent: July 5, 2016Assignee: OLEG ILIICH EPSHTEINInventor: Oleg Iliich Epshtein
-
Patent number: 9334330Abstract: The monoclonal antibodies that only recognize the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognizing the O-acetylated GD2 molecules expressed by the tumoral cells and not recognizing the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.Type: GrantFiled: December 23, 2014Date of Patent: May 10, 2016Assignee: UNIVERSITE DE NANTESInventors: Stephane Birkle, Jean-Marie Mussini, Jacques Aubry, Jacques Barbet, Jean-Francois Chatal, Beatrice Clemenceau
-
Patent number: 9290558Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.Type: GrantFiled: December 3, 2012Date of Patent: March 22, 2016Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Jill Wykosky, Denise Mazess Herpai
-
Patent number: 9289469Abstract: This document provides methods and materials involved in depleting immunosuppressive monocytes (e.g., CD14+/DR? or CD14+/DRlow monocytes) within a mammal. For example, methods and materials involved in using a CD2 binding molecule (e.g., alefacept) to deplete immunosuppressive monocytes within a mammal (e.g., a human) are provided.Type: GrantFiled: September 7, 2010Date of Patent: March 22, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: Ryan A. Wilcox, Thomas E. Witzig